COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3018 participants.

Also called NCT04642430

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,018 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04642430
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04642430. Randomized; single masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Acronym
COBRRA-AF
Intervention (Drug)
Apixaban
Intervention (Drug)
Rivaroxaban
Lead sponsor
Ottawa Hospital Research Institute (class: other)
Collaborator
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network (class: research network)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct04642430
Content hash
c3ca09cce8bb0ef3e24730d36b1ab36aa6a283a83ece604560cb72e2c759beca